Immunocore (NASDAQ:IMCR) Cut to Neutral at Mizuho

Mizuho cut shares of Immunocore (NASDAQ:IMCR) from an outperform rating to a neutral rating in a research report report published on Monday, Marketbeat reports. They currently have $38.00 price target on the stock, down from their previous price target of $72.00.

IMCR has been the topic of a number of other research reports. Oppenheimer restated an “outperform” rating and set a $89.00 price target (up previously from $87.00) on shares of Immunocore in a research note on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Immunocore in a research report on Thursday, October 24th. UBS Group began coverage on Immunocore in a report on Thursday, October 24th. They set a “sell” rating and a $24.00 target price for the company. Morgan Stanley cut their price target on shares of Immunocore from $80.00 to $74.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Finally, Guggenheim cut shares of Immunocore from a “buy” rating to a “neutral” rating in a research note on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $69.18.

Immunocore Stock Down 4.5 %

NASDAQ:IMCR opened at $32.62 on Monday. The company’s 50-day simple moving average is $32.52 and its 200-day simple moving average is $38.89. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. Immunocore has a fifty-two week low of $29.72 and a fifty-two week high of $76.98. The stock has a market capitalization of $1.63 billion, a P/E ratio of -34.34 and a beta of 0.72.

Immunocore (NASDAQ:IMCR) last announced its earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.50. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The company had revenue of $80.25 million during the quarter, compared to the consensus estimate of $78.94 million. During the same period last year, the firm earned ($0.59) earnings per share. Immunocore’s revenue was up 23.7% compared to the same quarter last year. On average, equities analysts anticipate that Immunocore will post -0.96 earnings per share for the current fiscal year.

Institutional Trading of Immunocore

A number of institutional investors and hedge funds have recently made changes to their positions in IMCR. Bellevue Group AG lifted its position in shares of Immunocore by 4.4% in the third quarter. Bellevue Group AG now owns 1,205,464 shares of the company’s stock valued at $37,526,000 after acquiring an additional 50,810 shares in the last quarter. Verition Fund Management LLC acquired a new stake in shares of Immunocore in the third quarter valued at about $739,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Immunocore by 7,437.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 92,257 shares of the company’s stock valued at $2,872,000 after acquiring an additional 91,033 shares in the last quarter. FMR LLC grew its stake in Immunocore by 0.5% during the 3rd quarter. FMR LLC now owns 4,836,040 shares of the company’s stock valued at $150,546,000 after acquiring an additional 23,436 shares in the last quarter. Finally, Alpha DNA Investment Management LLC acquired a new stake in Immunocore in the 3rd quarter valued at about $411,000. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.